3-Ethylphenylboronic acid | CAS:90555-65-0

We serve 3-Ethylphenylboronic acid CAS:90555-65-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Ethylphenylboronic acid

Product Name: 3-Ethylphenylboronic acid
Other Name:
3-Ethylphenylboronic acid
(3-ethylphenyl)boronic acid
CAS No: 90555-65-0
MF: C8H11BO2
MW: 149.98300
Density: 1.07g/cm3
Boiling point: 299.6ºC at 760mmHg
Melting point: 102.5-107.5ºC
Flash point: 135ºC
Refractive index: 1.521
UN Number: Non-dangerous goods
Transport hazard class: Non-dangerous goods
Packing group: Non-dangerous goods
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 3-Ethylphenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3-ethylphenyl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Ethylphenylboronic acid Use and application,(3-ethylphenyl)boronic acid technical grade,usp/ep/jp grade.


Related News: In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.Methyltris(methylethylketoxime)silane manufacturer The videos have gone viral on Chinese social media and have been praised as a novel way to raise awareness of the disease.2-Methyl-4-[(2-methylbenzoyl)amino]benzoic acid supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.3-BROMO-2-HYDROXY-5-METHYLPYRIDINE vendor Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”This includes chemical APIs.